OnKure Therapeutics, Inc.
General ticker "OKUR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $47.3M (TTM average)
OnKure Therapeutics, Inc. follows the US Stock Market performance with the rate: 29.5%.
Estimated limits based on current volatility of 5.0%: low 2.47$, high 2.72$
Factors to consider:
- Total employees count: 45 (-2.2%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Need additional capital, Clinical trial failure, Regulatory and compliance, Manufacturing limitations, Intellectual property risks
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.95$, 5.33$]
- 2026-12-31 to 2027-12-31 estimated range: [1.92$, 5.15$]
Financial Metrics affecting the OKUR estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: -0.14 < Investing cash flow per share per price, % of -0.12
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term OKUR quotes
Long-term OKUR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $36.93MM | $54.39MM | $62.95MM |
| Operating Income | $-36.93MM | $-54.39MM | $-62.95MM |
| Non-Operating Income | $3.25MM | $3.43MM | $3.43MM |
| Interest Expense | $0.00MM | $0.30MM | $0.00MM |
| R&D Expense | $32.12MM | $43.80MM | $48.26MM |
| Income(Loss) | $-33.69MM | $-50.96MM | $-59.52MM |
| Net Income(Loss)* | $-35.31MM | $-52.67MM | $-59.52MM |
| Stockholders Equity | $88.61MM | $103.83MM | $56.18MM |
| Assets | $107.44MM | $114.91MM | $62.12MM |
| Operating Cash Flow | $-34.55MM | $-51.12MM | $-51.83MM |
| Capital expenditure | $0.25MM | $0.05MM | $0.05MM |
| Investing Cash Flow | $-0.25MM | $15.87MM | $-0.05MM |
| Financing Cash Flow | $53.12MM | $116.13MM | $0.16MM |
| Earnings Per Share** | $-2.65 | $-3.95 | $-4.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.